Skip to main content
Top
Published in: Rheumatology International 5/2007

01-03-2007 | Original article

Effects of balneotherapy on serum IL-1, PGE2 and LTB4 levels in fibromyalgia patients

Authors: Füsun Ardıç, Merih Özgen, Hülya Aybek, Simin Rota, Duygu Çubukçu, Ali Gökgöz

Published in: Rheumatology International | Issue 5/2007

Login to get access

Abstract

The purpose of this study was to investigate the clinical effects of balneotherapy in the treatment of Fibromyalgia Syndrome (FMS) and to determine if balneotherapy influences serum levels of inflammation markers, IL-1, PGE2 and LTB4. 24 primary fibromyalgia female patients diagnosed according to American College of Rheumatology criteria were included to the study. Their ages ranged between 33 and 55 years. FMS patients were randomly assigned in two groups as, group 1 (n = 12) and group 2 (n = 12). Group 1 received 20-min bathing, once in a day for five days per week. Patients participated in the study for 3 weeks (total of 15 sessions) in Denizli. Group 2 did not receive balneotherapy. FMS patients were evaluated by tenderness measurements (tender point count and algometry), Visual Analogue Scale, Beck’s Depression Index, Fibromyalgia Impact Questionnaire. Ten healthy women recruited group three as the controls. Serum PGE2, LTB4 and IL1-α levels were measured in all three groups. The biochemical measurements and clinical assessments were performed before and at the end of general period of therapy. Statistically significant alterations in algometric score, Visual Analogue score, Beck’s Depression Index and PGE2 levels (< 0.001), numbers of tender points (< 0.01) and Fibromyalgia Impact Questionnaire score (< 0.05) were found after the balneotherapy between group 1 and 2. Mean PGE2 level of FMS patients were higher compared to healthy control group (< 0.0001) and decreased after the treatment period, only in group 1 (< 0.05). As in the group 2 and 3, detectable IL-1 and LTB4 measurements were insufficient, statistical analysis was performed, only in group 1. After balneotherapy IL-1 and LTB4 significantly decreased in group 1 (< 0.05). In conclusion, balneotherapy is an effective choice of treatment in patients with FMS relieving the clinical symptoms, and possibly influencing the inflammatory mediators.
Literature
1.
go back to reference Inanici F, Yunus MB (2004) History of fibromyalgia: past to present. Curr Pain Headache Rep 8 (5):369–378PubMed Inanici F, Yunus MB (2004) History of fibromyalgia: past to present. Curr Pain Headache Rep 8 (5):369–378PubMed
2.
go back to reference Sprott H (2003) What can rehabilitation interventions achieve in patients with primary fibromyalgia? Review. Curr Opin Rheumatol 15(2):145–50PubMedCrossRef Sprott H (2003) What can rehabilitation interventions achieve in patients with primary fibromyalgia? Review. Curr Opin Rheumatol 15(2):145–50PubMedCrossRef
3.
go back to reference Blanco LE, de Serres FJ, Fernandez-Bustillo E, Kassam DA, Arbesu D, Rodriguez C, Torre JC (2005) alpha1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Med Hypotheses 64(4):759–69PubMedCrossRef Blanco LE, de Serres FJ, Fernandez-Bustillo E, Kassam DA, Arbesu D, Rodriguez C, Torre JC (2005) alpha1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Med Hypotheses 64(4):759–69PubMedCrossRef
4.
go back to reference Sukenik S et al (1999) The role of spa therapy in various rheumatic diseases. Rheumatic Diseases Clinics of North America 25 (4):884 Sukenik S et al (1999) The role of spa therapy in various rheumatic diseases. Rheumatic Diseases Clinics of North America 25 (4):884
5.
go back to reference Cechettin M, Bellometti S, Lalli A, Galzigna L (1995) Serum interleukin-1 changes in arthrosis patients after mud-pack treatment. Phys Rehab Kur Med 5:92–93CrossRef Cechettin M, Bellometti S, Lalli A, Galzigna L (1995) Serum interleukin-1 changes in arthrosis patients after mud-pack treatment. Phys Rehab Kur Med 5:92–93CrossRef
6.
go back to reference Bellometti S, Giannini S, Sartori L, Crepaldi G (1997) Cytokine levels in osteoarthrosis patients undergoing mud bath therapy. Int J Clin Pharmacol Res 17(4):149–53PubMed Bellometti S, Giannini S, Sartori L, Crepaldi G (1997) Cytokine levels in osteoarthrosis patients undergoing mud bath therapy. Int J Clin Pharmacol Res 17(4):149–53PubMed
7.
go back to reference Bellometti S., Galzigna L (1998) Serum levels of a prostaglandin and a leukotriene after thermal mud pack therapy. Journal of Investigative Medicine 46:140–145PubMed Bellometti S., Galzigna L (1998) Serum levels of a prostaglandin and a leukotriene after thermal mud pack therapy. Journal of Investigative Medicine 46:140–145PubMed
8.
go back to reference Altan L, Bingöl Ü, Aykaç M, Koç Z, Yurtkuran M (2003) Investigation of the effects of pool-based exercise on fibromyalgia syndrome. Rheumatol Int 24:272–277PubMed Altan L, Bingöl Ü, Aykaç M, Koç Z, Yurtkuran M (2003) Investigation of the effects of pool-based exercise on fibromyalgia syndrome. Rheumatol Int 24:272–277PubMed
9.
go back to reference Buskila D, Abu-Shakra M, Neumann L et al (2001) Balneotherapy for fibromyalgia at the Dead Sea. Rheumatol Int 20:105–108PubMedCrossRef Buskila D, Abu-Shakra M, Neumann L et al (2001) Balneotherapy for fibromyalgia at the Dead Sea. Rheumatol Int 20:105–108PubMedCrossRef
10.
go back to reference Evcik D, Kizilay B, Gokcen E (2002) The effects of balneotherapy on fibromyalgia patients. Rheumatol Int 22:56–59PubMedCrossRef Evcik D, Kizilay B, Gokcen E (2002) The effects of balneotherapy on fibromyalgia patients. Rheumatol Int 22:56–59PubMedCrossRef
11.
go back to reference Donmez A, Karagulle MZ, Tercan N, Dinler M, Issever H, Karagulle M, Turan M (2005) SPA therapy in fibromyalgia: a randomised controlled clinic study. Rheumatol Int 26(2):168–72PubMedCrossRef Donmez A, Karagulle MZ, Tercan N, Dinler M, Issever H, Karagulle M, Turan M (2005) SPA therapy in fibromyalgia: a randomised controlled clinic study. Rheumatol Int 26(2):168–72PubMedCrossRef
12.
go back to reference Zijlstra TR, van de Laar MA, Bernelot Moens HJ, Taal E, Zakraoui L, Rasker JJ (2005) Spa treatment for primary fibromyalgia syndrome: a combination of thalassotherapy, exercise and patient education improves symptoms and quality of life. Rheumatology (Oxford) 44(4):539–46CrossRef Zijlstra TR, van de Laar MA, Bernelot Moens HJ, Taal E, Zakraoui L, Rasker JJ (2005) Spa treatment for primary fibromyalgia syndrome: a combination of thalassotherapy, exercise and patient education improves symptoms and quality of life. Rheumatology (Oxford) 44(4):539–46CrossRef
13.
go back to reference Wolfe F, Smythe HA, Yunus MB et al (1990) The American Collage of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 33:160–72 Wolfe F, Smythe HA, Yunus MB et al (1990) The American Collage of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 33:160–72
14.
go back to reference APHA (1989) Standard methods for the examination of water and wastewater, 19th edn. American Public Health Association, Washington APHA (1989) Standard methods for the examination of water and wastewater, 19th edn. American Public Health Association, Washington
15.
go back to reference Fisher AA (1986) Pressure threshold meter: its use for quantification of tender spots. Arch Phys Med Rehabil 67:836–838 Fisher AA (1986) Pressure threshold meter: its use for quantification of tender spots. Arch Phys Med Rehabil 67:836–838
16.
go back to reference Hewett JE, Buckelew SP, Johnson JC, Shaw SE, Huyser B, Fu YZ (1995) Selection of measures suitable for evaluating change in fibromyalgia clinical trials. J Rheumatol 22:953–958 Hewett JE, Buckelew SP, Johnson JC, Shaw SE, Huyser B, Fu YZ (1995) Selection of measures suitable for evaluating change in fibromyalgia clinical trials. J Rheumatol 22:953–958
17.
go back to reference Sarmer S, Ergin S, Yavuzer G (2000) The validity and reliability of the Turkish version of the Fibromyalgia impact questionnaire. Rheumatol Int 20:9–12PubMedCrossRef Sarmer S, Ergin S, Yavuzer G (2000) The validity and reliability of the Turkish version of the Fibromyalgia impact questionnaire. Rheumatol Int 20:9–12PubMedCrossRef
18.
go back to reference Burckhardt CS, Clark SR, Bennet RM (1991) The Fibromyalgia impact questionnaire: development and validation. J Rheumatol 18:728–733PubMed Burckhardt CS, Clark SR, Bennet RM (1991) The Fibromyalgia impact questionnaire: development and validation. J Rheumatol 18:728–733PubMed
19.
go back to reference Beck AT, Rush AJ, Shaw BF, Emergy G (1979) Cognitive therapy of depression. Guildford, New York Beck AT, Rush AJ, Shaw BF, Emergy G (1979) Cognitive therapy of depression. Guildford, New York
20.
go back to reference Yurtkuran M, Ay A, Karakoc Y (2005)Improvement of the clinical outcome in Ankylosing spondylitis by balneotherapy. Joint Bone Spine. 72(4):303–8PubMedCrossRef Yurtkuran M, Ay A, Karakoc Y (2005)Improvement of the clinical outcome in Ankylosing spondylitis by balneotherapy. Joint Bone Spine. 72(4):303–8PubMedCrossRef
21.
go back to reference Forestier R (2000) Magnitude and duration of the effects of two spa therapy courses on knee and hip osteoarthritis: an open prospective study in 51 consecutive patients. Joint Bone Spine 67:296–304PubMed Forestier R (2000) Magnitude and duration of the effects of two spa therapy courses on knee and hip osteoarthritis: an open prospective study in 51 consecutive patients. Joint Bone Spine 67:296–304PubMed
22.
go back to reference Yilmaz B, Goktepe AS, Alaca R, Mohur H, Kayar AH (2004) Comparison of a generic and a disease specific quality of life scale to assess a comprehensive spa therapy program for knee osteoarthritis. Joint Bone Spine 71(6):563–6PubMedCrossRef Yilmaz B, Goktepe AS, Alaca R, Mohur H, Kayar AH (2004) Comparison of a generic and a disease specific quality of life scale to assess a comprehensive spa therapy program for knee osteoarthritis. Joint Bone Spine 71(6):563–6PubMedCrossRef
23.
go back to reference Salemi S, Rethage J, Wollina U, Michel BA, Gay RE, Gay S, Sprott H. (2003) Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 30(1):146–50PubMed Salemi S, Rethage J, Wollina U, Michel BA, Gay RE, Gay S, Sprott H. (2003) Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 30(1):146–50PubMed
24.
go back to reference Hamaty D, Valentine JL, Howard R, Howard CW, Wakefield V, Patten MS (1989) The plasma endorphin, prostaglandin and catecholamine profile of patients with fibrositis treated with cyclobenzaprine and placebo: a 5-month study. J Rheumatol Suppl 19:164–8PubMed Hamaty D, Valentine JL, Howard R, Howard CW, Wakefield V, Patten MS (1989) The plasma endorphin, prostaglandin and catecholamine profile of patients with fibrositis treated with cyclobenzaprine and placebo: a 5-month study. J Rheumatol Suppl 19:164–8PubMed
25.
go back to reference Amel Kashipaz MR, Swinden D, Todd I, Powell RJ 2003) Normal production of inflammatory cytokines in chronic fatigue and fibromyalgia syndromes determined by intracellular cytokine staining in short-term cultured blood mononuclear cells. Clin Exp Immunol 132(2):360–5PubMedCrossRef Amel Kashipaz MR, Swinden D, Todd I, Powell RJ 2003) Normal production of inflammatory cytokines in chronic fatigue and fibromyalgia syndromes determined by intracellular cytokine staining in short-term cultured blood mononuclear cells. Clin Exp Immunol 132(2):360–5PubMedCrossRef
26.
go back to reference White DM (1996) mechanism of prostaglandin E2-induced substance P release from cultured sensory neurons. Neuroscience 70:561–65PubMedCrossRef White DM (1996) mechanism of prostaglandin E2-induced substance P release from cultured sensory neurons. Neuroscience 70:561–65PubMedCrossRef
27.
go back to reference Hedenberg-Magnusson B, Ernberg M, Alstergren P, Kopp S (2001) Pain mediation by prostaglandin E2 and leukotriene B4 in the human masseter muscle. Acta Odontol Scand. 59(6):348–55PubMedCrossRef Hedenberg-Magnusson B, Ernberg M, Alstergren P, Kopp S (2001) Pain mediation by prostaglandin E2 and leukotriene B4 in the human masseter muscle. Acta Odontol Scand. 59(6):348–55PubMedCrossRef
28.
go back to reference Hedenberg-Magnusson B, Ernberg M, Alstergren P, Kopp S. (2002) Effect on prostaglandin E2 and leukotriene B4 levels by local administration of glucocorticoid in human masseter muscle myalgia. Acta Odontol Scand 60(1):29–36PubMedCrossRef Hedenberg-Magnusson B, Ernberg M, Alstergren P, Kopp S. (2002) Effect on prostaglandin E2 and leukotriene B4 levels by local administration of glucocorticoid in human masseter muscle myalgia. Acta Odontol Scand 60(1):29–36PubMedCrossRef
29.
go back to reference Valitutti S et al (1990) Effects of sulphurus “thermal” water on T lymphocyte proliferative response. Ann Allergy 65:463–468PubMed Valitutti S et al (1990) Effects of sulphurus “thermal” water on T lymphocyte proliferative response. Ann Allergy 65:463–468PubMed
Metadata
Title
Effects of balneotherapy on serum IL-1, PGE2 and LTB4 levels in fibromyalgia patients
Authors
Füsun Ardıç
Merih Özgen
Hülya Aybek
Simin Rota
Duygu Çubukçu
Ali Gökgöz
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-006-0237-x

Other articles of this Issue 5/2007

Rheumatology International 5/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.